Through this acquisition, Orchid intends to increase its presence in the US market and to market its generic products directly to US customers.

Karalex Pharma is a leading provider of generic pharmaceuticals focused exclusively on the US healthcare market. Karalex Pharma, LLC, was launched in 2007 as a pharmaceutical company committed to becoming a leading provider of marketing and sales services to US classes of trade for developers and manufacturers of generic pharmaceuticals. Karalex Pharma has launched over 100 generic pharmaceutical products in the US with a combined value in excess of US$1 billion.

Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals said “we are happy that we have established our presence in the generic sales and marketing area with this acquisition. This acquisition will provide a strong commercial US-based sales capability to Orchid”.

The move is expected to pave the way for Orchid’s upcoming generic pharmaceuticals pipeline. It also means that Orchid, for the first time, has complete coverage of the entire generic pharmaceutical business cycle from product development to product sales.

Reference:

Orchid News Updates, Orchid to acquire US-based marketing company Karalex Pharma, LLC, 10 June 2010